Adoram Therapeutics SA

Multi-asset pre-clinical stage Biotech startup

Adoram Therapeutics is a spin-off from the University of Geneva, discovering next generation small molecule therapies for cancer and inflammation based around GPCR drug targets, the largest class of receptors in the human genome. Adoram specializes in small molecule drugs that have a sought after 'allosteric' mode of action, making them safer and more effective than conventional small molecules. Company founders include Dr. David Pejoski (Co-CEO / COO), Dr. Hesham Hamed (Co-CEO / CSO), and drug discovery advisor Prof. Leonardo Scapozza.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
REGISTER

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (10'000) 2023

Website

Venture Leaders Biotech

Venture Leaders Biotech 2024

Adoram Therapeutics SA

Multi-asset pre-clinical stage Biotech startup

Website:
adoram.ch

Headquarter:
Grand-Lancy

Foundation Date:
June 2022

Technology:

  • Biotech

Sectors:

  • Biotech
  • Cancer
  • Drug discovery
  • Inflammation
  • Research and development
  • Small molecule drugs

Support received

  • Support venture leaders
  • Support venturekick